Brimonidine Tartrate CAS 70359-46-5 Assay 99.0% ~ 101.0%
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili weBrimonidine Tartrate (CAS: 70359-46-5) kunye nomgangatho ophezulu.Ukukhetha i-α2-adrenergic receptor agonist, ichiza elisetyenziselwa ukunyanga i-glaucoma evulekile okanye i-ocular hypertension.I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga iBrimonidine Tartrate,Please contact: alvin@ruifuchem.com
| Igama leMchiza | I-Brimonidine Tartrate |
| Izithethantonye | I-Brimonidine L-Tartrate;UK 14304 Tartrate;I-AGN190342 Tartrate;I-5-Bromo-N- (4,5-Dihydro-1H-Imidazol-2-yl) i-quinoxalin-6-Amine Tartrate;I-5-Bromo-N- (4,5-Dihydro-1H-Imidazol-2-yl)-6-Quinoxalinamine Tartrate;5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)quinoxalin-6-Amine (2R,3R)-2,3-Dihydroxysuccinate |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoRhwebo |
| Inombolo yeCAS | 70359-46-5 |
| Ifomula yeemolekyuli | C11H10BrN5·C4H6O6 |
| Ubunzima beMolekyuli | 442.23 g/mol |
| Indawo yokunyibilika | 207.0~208.0℃(Disemba) |
| Inovakalelo | Ukungeva kuMoya, Ubushushu abuva |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Imvelaphi | Shanghai, China |
| Beka ubomi kwishelufa | Iinyanga ezingama-24 ukuba zigcinwe ngokufanelekileyo |
| Udidi | I-API (Isithako soXwebhu esiSebenzayo) |
| Uphawu | Ruifu Chemical |
| Izinto | Iinkcukacha | Iziphumo |
| Imbonakalo | Mhlophe okanye Mthubi Kancinane okanye Kancinci umgubo omdaka | Iyahambelana |
| Isazisi A | Ujikelezo oluKhethekileyo lwe-Optical | Iyahambelana |
| Isazisi B | I-Infrared Absorption Spectrophotometry | Iyahambelana |
| Ukunyibilika | Inyibilika emanzini, ayinyibiliki kwi-ethanol ene-anhydrous nakwitoluene | Iyahambelana |
| Ujikelezo oluKhethekileyo lwe-Optical | +9.0 ° ~ +10.5 ° | + 9,6 ° |
| Ilahleko ekomisweni | ≤0.50% | 0.20% |
| Uthuthu lweSulfated | ≤0.20% | 0.07% |
| Iintsimbi ezinzima | ≤20ppm | <20ppm |
| Izinto ezinxulumeneyo | ||
| Ukungcola Okuchaziweyo | ||
| N-(imidazolidin2ylidene)quinoxalin-6-amine | ≤0.10% | Iyahambelana |
| I-5-bromoqulinoxalin-6-amine | ≤0.10% | Iyahambelana |
| I-Quinoxalin-6-amine | ≤0.10% | Iyahambelana |
| 1-(5-bromoquinoxalin-6-yl) thiourea | ≤0.10% | Iyahambelana |
| I-2-(5-bromoquinoxalin-6-yl) i-guanidine | ≤0.10% | Iyahambelana |
| 5-bromo-N-(1H-imidazol-2-yl)Quinoxalin-6-amine | ≤0.10% | Iyahambelana |
| 1-(2-aminoethyl)-3-(5-bromoquinoxalin-6-yl) urea | ≤0.10% | Iyahambelana |
| Ukungcola Okungachazwanga | ≤0.10% | Iyahambelana |
| Iyonke | ≤0.20% | 0.12% |
| Isivavanyi | 99.0%~101.0%(kwisiseko esomileyo) | 99.8% |
| Ukuqukumbela | Le mveliso ngokuhlola ihambelana neBP2015 Standard | |
Umqulu:Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina isikhongozeli sivalwe ngokuqinileyo kwaye usigcine kwindawo epholileyo, eyomileyo (2~8℃) kunye nendawo yokugcina impahla engena moya ikude kwizinto ezingahambelaniyo.Kuphephe ukuchanabeka kwilanga elithe ngqo, ukufuma kunye nobushushu obugqithisileyo.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Ukuthenga njani?Nceda uqhagamshelaneDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Amava Eminyaka Eli-15?Sineminyaka engaphezu kwe-15 yamava ekwenziweni nasekuthumeleni kumazwe angaphandle uluhlu olubanzi oluphezulu lwamayeza aphakathi okanye amachiza alungileyo.
Iimarike eziphambili?Thengisa kwimarike yasekhaya, eMntla Melika, eYurophu, eIndiya, eKorea, eJapan, eOstreliya, njl.
Iingenelo?Umgangatho ophezulu, ixabiso elifikelelekayo, iinkonzo zengcali kunye nenkxaso yobugcisa, ukuhanjiswa ngokukhawuleza.
UmgangathoIsiqinisekiso?Inkqubo yokulawula umgangatho ongqongqo.Izixhobo zobuchwephesha zokuhlalutya ziquka i-NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, njl.
Iisampulu?Uninzi lweemveliso zibonelela ngeesampulu zasimahla zokuvavanya umgangatho, iindleko zokuthumela kufuneka zihlawulwe ngabathengi.
Factory Audit?Uphicotho-zincwadi lwasefektri wamkelekile.Nceda wenze idinga kwangaphambili.
MOQ?Akukho MOQ.Umyalelo omncinci wamkelekile.
Ixesha lokuzisa? Ukuba ngaphakathi kwesitokhwe, ukuhanjiswa kweentsuku ezintathu kuqinisekisiwe.
Ezothutho?Nge-Express (FedEx, DHL), ngoMoya, ngoLwandle.
Amaxwebhu?Emva kwenkonzo yokuthengisa: I-COA, i-MOA, i-ROS, i-MSDS, njl.
Udibaniso lweSiko?Inokubonelela ngeenkonzo zesiko lokudibanisa ukuze zilungele iimfuno zakho zophando.
Immimiselo yokuhlawula?I-invoyisi yeProforma iya kuthunyelwa kuqala emva kokuqinisekiswa kwe-odolo, efakwe kwiinkcukacha zethu zebhanki.Intlawulo nge-T / T (i-Telex Transfer), i-PayPal, i-Western Union, njl.
IiNgxelo zeNgozi H301: Ityhefu xa iginyiwe.
IiNkcazo zokuQaphela
I-P501: Lahla iziqulatho/isikhongozeli kwiziko elivunyiweyo lokulahla inkunkuma.
P270: Ungatyi, ungaseli okanye utshaye xa usebenzisa le mveliso.
P264: Hlamba ulusu ngononophelo emva kokuphatha.
I-P301 + P310 + P330: UKUBA IYAGINWA: Ngoko nangoko fowunela i-POISON CENTER/ugqirha.Hlamba umlomo.
P405: Ivenkile itshixiwe.
Imithetho eNxulumeneyo:
Ulwazi lwezoThutho:
Inombolo ye-UN (DOT-AIR) UN2811
Udidi (DOT-AIR) 6.1
IQela lokuPakisha (TCI-A) III
Inombolo yeHS 2933.29.9000
I-Brimonidine Tartrate (i-CAS: 70359-46-5) i-blocker ekhethiweyo kakhulu ye-α2-receptor, ephuhliswe ngempumelelo yi-US Inkampani ye-Allergan, yonyango lwamehlo.Inokunciphisa uxinzelelo lwe-intraocular (IOP).I-Brimonidine Tartrate isisombululo se-ophthalmic saling kwimarike yifomu ye-Brimonidine Tartrate, eliyeza elilungileyo le-IOP-lehlisa i-glaucoma evulekile-engileyo engapheliyo kunye nonyango lwe-ocular hypertension yezigulana, kodwa nakumanqanaba e-argon laser IOP.Isisombululo se-Brimonidine Tartrate ophthalmic sineendlela ezimbini zesenzo ngokunciphisa imveliso ye-aqueous humor kunye nokwandisa i-pigment layer ye-liquid scleral outflow therapy ngeenjongo zonyango.Emva kokulahla iliso, umphumo ukhawuleza, kwaye unokufikelela kwincopho xa usebenzisa ukuya kwi-2h, kwaye ixesha elisebenzayo linokugcina i-12h.Igazi liyakwazi ukubona kuphela iithontsi zamachiza.Le mveliso ine-metabolism yokuqala yokudlula kwisibindi, kwaye i-metabolites ekhutshwe kumchamo ngezintso.Ukufakwa kwenkqubo kunye nokusabalalisa akuchaphazeli, kwaye abantu abadala abafuni ukulungiswa kwedosi.I-Brimonidine Tartrate isisombululo se-ophthalmic xa kuthelekiswa nezinye i-α-blockers, i-fat-soluble incinci, ngelixa ingekho lula ukudlula umqobo wegazi-ingqondo kwaye ayivelisi i-sedation, hypotension kunye nezinye i-clonidine central reactions ezimbi.I-Brimonidine Tartrate Ophthalmic Solution ikhetha kakhulu i-α2-adrenergic receptors, kunye ne-α2 / α1 umlinganiselo we-receptor affinity ngaphezu kwamaxesha e-1000.Umphumo we-alpha 2 receptors unokukhokelela ekunciphiseni uxinzelelo lwe-intraocular.Kwaye indima ye-alpha 1 i-receptors ingakhokelela kwi-vascular contraction, ukuchithwa kwe-eyelid okanye ukunciphisa kunye nokunciphisa umfundi.Ukusetyenziswa kwexesha elide kwale mveliso akusayi kubangela ukudakumba ngokukhawuleza.Ukongezelela, xa kuthelekiswa ne-β-blockers, i-Brimonidine Tartrate eyehlayo kwimiphumo emincinci ye-cardiovascular effects, ayinayo impembelelo ekusebenzeni kwemiphunga, ngoko ifanelekile kwizigulane ezikhubazekileyo ze-β-blockers.Ngaphaya koko, xa isetyenziswa yodwa i-β-blocker, ayinakufezekisa iinjongo zonyango, kwaye unokonyusa ngaxeshanye i-FDA.
